forecast glp-1 prescriptions growth 2025 Receptor Agonist Market Size and Strategies To 2035 GLP-1 Diabetes Treatment Drugs Market

Instead, it looks more like a christmas present for big pharma, wrapped in a patient safety bow

There is insufficient data on liraglutide excretion in human breast milk, which is why breastfeeding is not advised during treatment

K., Kahn, S

This is supported by research: A 40-week study published in The Lancet Diabetes & Endocrinology found that semaglutide was better at improving blood sugar control and decreasing body weight and helped more participants with type 2 diabetes lose weight and reach their target blood sugar levels than dulaglutide

This study was funded by Sanofi US, Inc

The approved BMI thresholds match the FDA standard: 30 or higher, or 27 or higher with at least one weight-related comorbidity